Name | Description | Patent Applicant | Current Assignee | Inventor | Patent Jurisdiction | Patent Number | Date of Patent | ||
---|---|---|---|---|---|---|---|---|---|
Patent 9649320 was granted and assigned to ReveraGen BioPharma on May, 2017 by the United States Patent and Trademark Office. | 9649320 | May 16, 2017 | |||||||
Patent 11382922 was granted and assigned to ReveraGen BioPharma on July, 2022 by the United States Patent and Trademark Office. | 11382922 | July 12, 2022 | |||||||
Patent 9434758 was granted and assigned to ReveraGen BioPharma on September, 2016 by the United States Patent and Trademark Office. | 9434758 | September 6, 2016 | |||||||
Patent 11471471 was granted and assigned to ReveraGen BioPharma on October, 2022 by the United States Patent and Trademark Office. | 11471471 | October 18, 2022 | |||||||
Patent 9198921 was granted and assigned to ReveraGen BioPharma on December, 2015 by the United States Patent and Trademark Office. | 9198921 | December 1, 2015 | |||||||
Patent 10464967 was granted and assigned to ReveraGen BioPharma on November, 2019 by the United States Patent and Trademark Office. | 10464967 | November 5, 2019 | |||||||
Patent 10206933 was granted and assigned to ReveraGen BioPharma on February, 2019 by the United States Patent and Trademark Office. | 10206933 | February 19, 2019 | |||||||
Patent 10857161 was granted and assigned to ReveraGen BioPharma on December, 2020 by the United States Patent and Trademark Office. | 10857161 | December 8, 2020 | |||||||
Patent 10799514 was granted and assigned to ReveraGen BioPharma on October, 2020 by the United States Patent and Trademark Office. | 10799514 | October 13, 2020 | |||||||
Patent 10000525 was granted and assigned to ReveraGen BioPharma on June, 2018 by the United States Patent and Trademark Office. | 10000525 | June 19, 2018 | |||||||
Patent 9637738 was granted and assigned to ReveraGen BioPharma on May, 2017 by the United States Patent and Trademark Office. | 9637738 | May 2, 2017 | |||||||
11690853 | July 4, 2023 |